{"id":76492,"date":"2026-08-25T12:12:25","date_gmt":"2026-08-25T04:12:25","guid":{"rendered":"https:\/\/flcube.com\/?p=76492"},"modified":"2026-08-25T12:12:26","modified_gmt":"2026-08-25T04:12:26","slug":"antengene-clears-australian-regulatory-hurdles-for-phase-i-attract-study-of-ucb-licensed-atg-201","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76492","title":{"rendered":"Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB\u2011Licensed ATG\u2011201"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Antengene Corporation Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/6996:HKG\">HKG: 6996<\/a>) announced that the <strong>Phase I ATTRACT study<\/strong> of its proprietary compound <strong>ATG\u2011201<\/strong> has been approved by the <strong>Human Research Ethics Committee (HREC)<\/strong> in Australia, and the <strong>Clinical Trial Notification (CTN)<\/strong> scheme with the <strong>Therapeutic Goods Administration (TGA)<\/strong> has been completed \u2014 clearing the path for first\u2011in\u2011human evaluation of the CD19\/CD3 bispecific antibody.<\/p>\n\n\n\n<h2 id=\"h-clinical-milestone\" class=\"wp-block-heading\">Clinical Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Antengene Corporation Limited (HKG: 6996)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>ATG\u2011201 (CD19\/CD3 bispecific antibody \/ T\u2011cell engager)<\/td><\/tr><tr><td><strong>Study<\/strong><\/td><td>Phase I ATTRACT<\/td><\/tr><tr><td><strong>Ethics Approval<\/strong><\/td><td>Human Research Ethics Committee (HREC), Australia<\/td><\/tr><tr><td><strong>Regulatory Step<\/strong><\/td><td>Clinical Trial Notification (CTN) with the TGA completed<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>25 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>CD19\/CD3 bispecific antibody<\/strong> functioning as a <strong>T\u2011cell engager<\/strong><\/li>\n\n\n\n<li><strong>Platform Technology:<\/strong> Utilizes <strong>steric hindrance masking technology<\/strong>, a design approach intended to improve the safety and controllability of T\u2011cell engagement<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Designed to <strong>deplete CD19\u2011expressing B cells<\/strong>, a strategy with established relevance in B\u2011cell\u2011mediated diseases<\/li>\n\n\n\n<li><strong>Therapeutic Potential:<\/strong> B\u2011cell depletion via CD19 targeting is a validated approach in hematological malignancies and autoimmune indications, positioning ATG\u2011201 within a competitive and rapidly evolving therapeutic landscape<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-partnership-context\" class=\"wp-block-heading\">Partnership Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>UCB Licensing Deal:<\/strong> In <strong>March 2026<\/strong>, Antengene entered into an <strong>exclusive licensing agreement worth up to USD 1.18 billion<\/strong> with <strong>UCB<\/strong>, granting the Belgian biopharmaceutical company <strong>exclusive global rights<\/strong> to develop, manufacture and commercialize <strong>ATG\u2011201<\/strong>.<\/li>\n\n\n\n<li><strong>Validation Signal:<\/strong> The partnership with UCB provides external validation of the asset&#8217;s potential and supplies development resources beyond Antengene&#8217;s own balance sheet.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-outlook\" class=\"wp-block-heading\">Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011in\u2011Human Progression:<\/strong> With HREC approval and TGA CTN completion, Antengene and UCB can now advance the <strong>ATTRACT Phase I study<\/strong> in Australia, a common early\u2011clinical site given its streamlined regulatory pathway.<\/li>\n\n\n\n<li><strong>Pipeline Momentum:<\/strong> The milestone adds to Antengene&#8217;s growing international clinical footprint and reinforces its bispecific antibody platform as a core growth driver.<\/li>\n\n\n\n<li><strong>B\u2011Cell Depletion Landscape:<\/strong> As CD19\u2011targeted approaches gain traction globally, early safety and pharmacology data from the ATTRACT study will be closely watched for differentiation signals versus existing B\u2011cell depletion therapies.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the development timeline, regulatory pathway and commercial prospects of ATG\u2011201 under the Antengene\u2013UCB collaboration. Actual results may differ due to risks including clinical outcomes, regulatory decisions and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082500048_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026082500048_c.\"><\/object><a id=\"wp-block-file--media-6906918b-12df-4995-98fd-19e9cc81dafb\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082500048_c.pdf\">2026082500048_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082500048_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-6906918b-12df-4995-98fd-19e9cc81dafb\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Antengene Corporation Limited (HKG: 6996) announced that the Phase I ATTRACT study of its proprietary&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[136,62,926,2790],"class_list":["post-76492","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-antengene","tag-clinical-trial-approval-initiation","tag-hkg-6996","tag-t-cell-engager"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB\u2011Licensed ATG\u2011201 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Antengene Corporation Limited (HKG: 6996) announced that the Phase I ATTRACT study of its proprietary compound ATG\u2011201 has been approved by the Human Research Ethics Committee (HREC) in Australia, and the Clinical Trial Notification (CTN) scheme with the Therapeutic Goods Administration (TGA) has been completed \u2014 clearing the path for first\u2011in\u2011human evaluation of the CD19\/CD3 bispecific antibody.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=76492\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB\u2011Licensed ATG\u2011201\" \/>\n<meta property=\"og:description\" content=\"Antengene Corporation Limited (HKG: 6996) announced that the Phase I ATTRACT study of its proprietary compound ATG\u2011201 has been approved by the Human Research Ethics Committee (HREC) in Australia, and the Clinical Trial Notification (CTN) scheme with the Therapeutic Goods Administration (TGA) has been completed \u2014 clearing the path for first\u2011in\u2011human evaluation of the CD19\/CD3 bispecific antibody.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=76492\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-25T04:12:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-25T04:12:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76492#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76492\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB\u2011Licensed ATG\u2011201\",\"datePublished\":\"2026-08-25T04:12:25+00:00\",\"dateModified\":\"2026-08-25T04:12:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76492\"},\"wordCount\":396,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Antengene\",\"Clinical trial approval \\\/ initiation\",\"HKG: 6996\",\"T cell engager\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76492#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76492\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=76492\",\"name\":\"Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB\u2011Licensed ATG\u2011201 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-25T04:12:25+00:00\",\"dateModified\":\"2026-08-25T04:12:26+00:00\",\"description\":\"Antengene Corporation Limited (HKG: 6996) announced that the Phase I ATTRACT study of its proprietary compound ATG\u2011201 has been approved by the Human Research Ethics Committee (HREC) in Australia, and the Clinical Trial Notification (CTN) scheme with the Therapeutic Goods Administration (TGA) has been completed \u2014 clearing the path for first\u2011in\u2011human evaluation of the CD19\\\/CD3 bispecific antibody.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76492#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76492\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76492#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB\u2011Licensed ATG\u2011201\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB\u2011Licensed ATG\u2011201 - Insight, China&#039;s Pharmaceutical Industry","description":"Antengene Corporation Limited (HKG: 6996) announced that the Phase I ATTRACT study of its proprietary compound ATG\u2011201 has been approved by the Human Research Ethics Committee (HREC) in Australia, and the Clinical Trial Notification (CTN) scheme with the Therapeutic Goods Administration (TGA) has been completed \u2014 clearing the path for first\u2011in\u2011human evaluation of the CD19\/CD3 bispecific antibody.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=76492","og_locale":"en_US","og_type":"article","og_title":"Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB\u2011Licensed ATG\u2011201","og_description":"Antengene Corporation Limited (HKG: 6996) announced that the Phase I ATTRACT study of its proprietary compound ATG\u2011201 has been approved by the Human Research Ethics Committee (HREC) in Australia, and the Clinical Trial Notification (CTN) scheme with the Therapeutic Goods Administration (TGA) has been completed \u2014 clearing the path for first\u2011in\u2011human evaluation of the CD19\/CD3 bispecific antibody.","og_url":"https:\/\/flcube.com\/?p=76492","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-25T04:12:25+00:00","article_modified_time":"2026-08-25T04:12:26+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=76492#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=76492"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB\u2011Licensed ATG\u2011201","datePublished":"2026-08-25T04:12:25+00:00","dateModified":"2026-08-25T04:12:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=76492"},"wordCount":396,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Antengene","Clinical trial approval \/ initiation","HKG: 6996","T cell engager"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=76492#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=76492","url":"https:\/\/flcube.com\/?p=76492","name":"Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB\u2011Licensed ATG\u2011201 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-25T04:12:25+00:00","dateModified":"2026-08-25T04:12:26+00:00","description":"Antengene Corporation Limited (HKG: 6996) announced that the Phase I ATTRACT study of its proprietary compound ATG\u2011201 has been approved by the Human Research Ethics Committee (HREC) in Australia, and the Clinical Trial Notification (CTN) scheme with the Therapeutic Goods Administration (TGA) has been completed \u2014 clearing the path for first\u2011in\u2011human evaluation of the CD19\/CD3 bispecific antibody.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=76492#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=76492"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=76492#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB\u2011Licensed ATG\u2011201"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76492","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76492"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76492\/revisions"}],"predecessor-version":[{"id":76495,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76492\/revisions\/76495"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76492"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76492"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76492"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}